pioglitazone has been researched along with Carcinoma, Renal Cell in 6 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Carcinoma, Renal Cell: A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.
Excerpt | Relevance | Reference |
---|---|---|
"We enrolled 45 patients with metastatic renal cell carcinoma (RCC) at a progressive disease between March 2003 and April 2008 to assess the impact of an anti-inflammatory treatment regime in combination with metronomic low-dose chemotherapy." | 2.77 | Pioglitazone, etoricoxib, interferon-α, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial. ( Andreesen, R; Berand, A; Bross, K; Grassinger, J; Reichle, A; Rogenhofer, S; Schrettenbrunner, I; Suedhoff, T; Vogelhuber, M; Walter, B; Wieland, WF; Wilke, J, 2012) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (50.00) | 29.6817 |
2010's | 2 (33.33) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
Authors | Studies |
---|---|
Piątkowska-Chmiel, I | 1 |
Gawrońska-Grzywacz, M | 1 |
Natorska-Chomicka, D | 1 |
Herbet, M | 1 |
Sysa, M | 1 |
Iwan, M | 1 |
Korga, A | 1 |
Dudka, J | 1 |
Walter, B | 1 |
Schrettenbrunner, I | 1 |
Vogelhuber, M | 1 |
Grassinger, J | 1 |
Bross, K | 1 |
Wilke, J | 1 |
Suedhoff, T | 1 |
Berand, A | 1 |
Wieland, WF | 1 |
Rogenhofer, S | 1 |
Andreesen, R | 1 |
Reichle, A | 1 |
Mahmoud, MF | 1 |
El Shazly, SM | 1 |
Yuan, J | 1 |
Takahashi, A | 1 |
Masumori, N | 1 |
Uchida, K | 1 |
Hisasue, S | 1 |
Kitamura, H | 1 |
Itoh, N | 1 |
Tsukamoto, T | 1 |
Yang, FG | 1 |
Zhang, ZW | 1 |
Xin, DQ | 1 |
Shi, CJ | 1 |
Wu, JP | 1 |
Guo, YL | 1 |
Guan, YF | 1 |
Inoue, K | 1 |
Kawahito, Y | 1 |
Tsubouchi, Y | 1 |
Kohno, M | 1 |
Yoshimura, R | 1 |
Yoshikawa, T | 1 |
Sano, H | 1 |
1 trial available for pioglitazone and Carcinoma, Renal Cell
Article | Year |
---|---|
Pioglitazone, etoricoxib, interferon-α, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antiviral Age | 2012 |
5 other studies available for pioglitazone and Carcinoma, Renal Cell
Article | Year |
---|---|
Pioglitazone as a modulator of the chemoresistance of renal cell adenocarcinoma to methotrexate.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Drug | 2020 |
Pioglitazone protects against cisplatin induced nephrotoxicity in rats and potentiates its anticancer activity against human renal adenocarcinoma cell lines.
Topics: Animals; Benzhydryl Compounds; Carcinoma, Renal Cell; Cell Line, Tumor; Cisplatin; Epoxy Compounds; | 2013 |
Ligands for peroxisome proliferator-activated receptor gamma have potent antitumor effect against human renal cell carcinoma.
Topics: Carcinoma, Renal Cell; Cell Division; Dose-Response Relationship, Drug; Humans; Kidney Neoplasms; Pi | 2005 |
Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Chrom | 2005 |
Expression of peroxisome proliferator-activated receptor gamma in renal cell carcinoma and growth inhibition by its agonists.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Renal Cell; Cell Division; Chromans; Coloring A | 2001 |